Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis

URN to cite this document:: urn:nbn:de:bvb:355-epub-586014
DOI to cite this document:: 10.5283/epub.58601

Denk, Alexander

; Mittermaier, Cornelia ; Weber, Daniela ; Fante, Matthias ; Güneş, Sibel ; Edinger, Matthias ; Herr, Wolfgang ; Wolff, Daniel

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 04 Jul 2024 06:30

Alternative links to fulltext:DOI Publisher

This publication is part of the DEAL contract with Springer.

Details

Preview

Export bibliographical data

Abstract

Steroid-refractory chronic graft-versus-host disease (cGvHD) is associated with significant morbidity and mortality, with ruxolitinib being the first drug approved for its treatment. We retrospectively analyzed the safety and efficacy of ruxolitinib for treatment of cGvHD at our center between 07/2015 and 12/2022 and identified 48 patients receiving ruxolitinib as second (18/48) or advanced ...